Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13

.

Source: Expert Opinion on Biological Therapy - August 30, 2020 Category: Drugs & Pharmacology Authors: Tommaso Lorenzo Parigi Ferdinando D ’Amico Laurent Peyrin-Biroulet Silvio Danese Source Type: research